These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23564375)

  • 1. Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia.
    Hayes S; Mudd PN; Ouellet D; Johnson BM; Williams D; Gibiansky E
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1507-20. PubMed ID: 23564375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
    Kellum A; Jagiello-Gruszfeld A; Bondarenko IN; Patwardhan R; Messam C; Mostafa Kamel Y
    Curr Med Res Opin; 2010 Oct; 26(10):2339-46. PubMed ID: 20735290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
    Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J
    Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
    Zhang J; Thapar M; Farrell C; Wire MB
    Pharm Res; 2015 Jun; 32(6):2015-28. PubMed ID: 25534682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease.
    Farrell C; Hayes SC; Wire M; Zhang J
    Br J Clin Pharmacol; 2014 Mar; 77(3):532-44. PubMed ID: 24117976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics, platelet response, and safety of eltrombopag at supratherapeutic doses of up to 200 mg once daily in healthy volunteers.
    Matthys G; Park JW; McGuire S; Wire MB; Bowen C; Williams D; Jenkins J; Peng B
    J Clin Pharmacol; 2011 Mar; 51(3):301-8. PubMed ID: 20418510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide.
    Chawla SP; Staddon A; Hendifar A; Messam CA; Patwardhan R; Kamel YM
    BMC Cancer; 2013 Mar; 13():121. PubMed ID: 23497336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM; Williams D; Deng Y; Uhl J; Kitchen V; Collins D; Erickson-Miller CL
    Blood; 2007 Jun; 109(11):4739-41. PubMed ID: 17327409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia.
    Yang R; Li J; Jin J; Huang M; Yu Z; Xu X; Zhang X; Hou M
    Br J Haematol; 2017 Jan; 176(1):101-110. PubMed ID: 27734464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
    Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
    Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.
    Winer ES; Safran H; Karaszewska B; Richards DA; Hartner L; Forget F; Ramlau R; Kumar K; Mayer B; Johnson BM; Messam CA; Mostafa Kamel Y
    Cancer Med; 2015 Jan; 4(1):16-26. PubMed ID: 25165041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura.
    Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM
    N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
    McHutchison JG; Dusheiko G; Shiffman ML; Rodriguez-Torres M; Sigal S; Bourliere M; Berg T; Gordon SC; Campbell FM; Theodore D; Blackman N; Jenkins J; Afdhal NH;
    N Engl J Med; 2007 Nov; 357(22):2227-36. PubMed ID: 18046027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.
    Afdhal NH; Giannini EG; Tayyab G; Mohsin A; Lee JW; Andriulli A; Jeffers L; McHutchison J; Chen PJ; Han KH; Campbell F; Hyde D; Brainsky A; Theodore D;
    N Engl J Med; 2012 Aug; 367(8):716-24. PubMed ID: 22913681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura.
    Zhang Y; Kolesar JM
    Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
    Cheng G; Saleh MN; Marcher C; Vasey S; Mayer B; Aivado M; Arning M; Stone NL; Bussel JB
    Lancet; 2011 Jan; 377(9763):393-402. PubMed ID: 20739054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.